Katherine L. Molnar-Kimber

2.6k citations

37 papers · 2.1k indexed · h-index 27

Co-authors: Steven Μ. Albelda William S. Mason Larry R. Kaiser Barry M. Weichman Jesse Summers Kunjlata M. Amin Daniel H. Sterman James M. Wilson
Topics: Virus-based gene therapy research (21 papers)Hepatitis B Virus Studies (7 papers)Herpesvirus Infections and Treatments (6 papers)
Cited by: Genetics Biotechnology Oncology
Journals: Proceedings of the National Academy of Sciences Journal of the American Chemical Society The Journal of Experimental Medicine
Partner nations: United States Canada Israel

In The Last Decade

Katherine L. Molnar-Kimber

37 papers receiving 2.0k citations

Peers

Countries citing papers authored by Katherine L. Molnar-Kimber

Since Specialization

Citations

This map shows the geographic impact of Katherine L. Molnar-Kimber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine L. Molnar-Kimber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine L. Molnar-Kimber more than expected).

Fields of papers citing papers by Katherine L. Molnar-Kimber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine L. Molnar-Kimber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine L. Molnar-Kimber. The network helps show where Katherine L. Molnar-Kimber may publish in the future.

Co-authorship network of co-authors of Katherine L. Molnar-Kimber

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine L. Molnar-Kimber. A scholar is included among the top collaborators of Katherine L. Molnar-Kimber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine L. Molnar-Kimber. Katherine L. Molnar-Kimber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Each type of cause that initiates rheumatoid arthritis or RA flares differentially affects the response to therapy 2011 ·Medical Hypotheses ·Katherine L. Molnar-Kimber,(unknown)	7
2	Replication-Selective Herpes Simplex Virus Type 1 Mutant Therapy of Cervical Cancer Is Enhanced by Low-Dose Radiation 2002 ·Human Gene Therapy ·Stephanie V. Blank,Stephen C. Rubin,George Coukos,Kunjlata M. Amin,Steven Μ. Albelda,Katherine L. Molnar-Kimber	52
3	Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy 2000 ·Cancer Gene Therapy ·George Coukos,Antonis Makrigiannakis,(unknown),Larry R. Kaiser,(unknown),Ivor Benjamin,Steven Μ. Albelda,Stephen C. Rubin,Katherine L. Molnar-Kimber	54
4	Use of Transcriptional Regulatory Sequences of Telomerase (hTER and hTERT) for Selective Killing of Cancer Cells 2000 ·Molecular Therapy ·Rula Abdul‐Ghani,Patricia Ohana,Imad Matouk,Suhail Ayesh,Basim M. Ayesh,Morris Laster,(unknown),Hilla Giladi,Katherine L. Molnar-Kimber,Maher A. Sughayer,Natalia Sánchez de Groot,Abraham Hochberg	65
5	Effect of Preexisting Anti-Herpes Immunity on the Efficacy of Herpes Simplex Viral Therapy in a Murine Intraperitoneal Tumor Model 2000 ·Molecular Therapy ·Eric S. Lambright,(unknown),Seth Force,Michael Lanuti,(unknown),Larry R. Kaiser,Steven M. Albelda,Katherine L. Molnar-Kimber	39
6	A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma 2000 ·Cancer Gene Therapy ·Daniel H. Sterman,Katherine L. Molnar-Kimber,(unknown),Michael Chang,Michael Lanuti,Kunjlata M. Amin,(unknown),Eugene Kang,Joseph Treat,Adri Recio,Leslie A. Litzky,James M. Wilson,(unknown),Steven M. Albelda	28
7	Combination Therapy with Lamivudine and Adenovirus Causes Transient Suppression of Chronic Woodchuck Hepatitis Virus Infections 2000 ·Journal of Virology ·Tianlun Zhou,(unknown),Frederick A. Nunes,Katherine L. Molnar-Kimber,James M. Wilson,Carol E. Aldrich,Jeffry Saputelli,Sam Litwin,Lynn D. Condreay,Christoph Seeger,William S. Mason	27
8	Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. 2000 ·PubMed ·George Coukos,Antonis Makrigiannakis,Eugene Kang,Stephen C. Rubin,Steven Μ. Albelda,Katherine L. Molnar-Kimber	55
9	Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system 1999 ·The Annals of Thoracic Surgery ·Eric S. Lambright,(unknown),Abbas E. Abbas,(unknown),George Coukos,Katherine L. Molnar-Kimber,(unknown)	17
10	Impact of Preexisting and Induced Humoral and Cellular Immune Responses in an Adenovirus-Based Gene Therapy Phase I Clinical Trial for Localized Mesothelioma 1998 ·Human Gene Therapy ·Katherine L. Molnar-Kimber,Daniel H. Sterman,Michael Chang,Eun Ha Kang,(unknown),Michael Lanuti,Ashraf A. Elshami,(unknown),James M. Wilson,Larry R. Kaiser,Steven Μ. Albelda	167
11	Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma. 1997 ·PubMed ·John C. Kucharczuk,B. Randazzo,Michael Y. Chang,K M Amin,Ashraf A. Elshami,Daniel H. Sterman,Nabil P. Rizk,Katherine L. Molnar-Kimber,Stuart M. Brown,Alasdair Maclean,Leslie A. Litzky,Nicholas Fraser,Steven Μ. Albelda,Larry R. Kaiser	96
12	Comparison of effects of sirolimus on cytokine dependent and cytokine independent proliferation 1995 ·Inflammation Research ·Katherine L. Molnar-Kimber,(unknown),(unknown),Haoze Chen,Suren N. Sehgal	2
13	A Putative Sirolimus (Rapamycin) Effector Protein 1994 ·Biochemical and Biophysical Research Communications ·(unknown),Hao Chen,(unknown),(unknown),(unknown),(unknown),Hongzhou Zhang,Cheston Hsiao,Kazuki Nakanishi,Katherine L. Molnar-Kimber	59
14	Modulation of TNFα and IL-1β from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors 1993 ·Inflammation Research ·Katherine L. Molnar-Kimber,(unknown),Richard J. Heaslip,Barry M. Weichman	55
15	Differential regulation of TNF‐α and IL‐1β production from endotoxin stimulated human monocytes by phosphodiesterase inhibitors 1992 ·Mediators of Inflammation ·Katherine L. Molnar-Kimber,(unknown),Richard J. Heaslip,Barry M. Weichman	28
16	Strategies for the development of new antiarthritic agents 1992 ·International Journal of Immunopharmacology ·Alan J. Lewis,Keith B. Glaser,(unknown),Katherine L. Molnar-Kimber,(unknown)	4
17	Adenovirus vaccine vectors expressing hepatitis B surface antigen: Importance of regulatory elements in the adenovirus major late intron 1990 ·Virology ·B B Mason,Alan R. Davis,(unknown),Murty Chengalvala,Michael D. Lubeck,(unknown),(unknown),(unknown),Surendra K. Dheer,Katherine L. Molnar-Kimber,Satoshi Mizutani,Paul P. Hung	31
18	High level expression of the envelope glycoproteins of the human immunodeficiency virus type I in presence of rev gene using helper-independent adenovirus type 7 recombinants 1990 ·Virology ·Pranab K. Chanda,Robert J. Natuk,B B Mason,(unknown),(unknown),Surendra K. Dheer,Katherine L. Molnar-Kimber,Satoshi Mizutani,Michael D. Lubeck,Alan R. Davis,Paul P. Hung	32
19	T cell clones with dual specificity for M1s and various major histocompatibility complex determinants. 1981 ·The Journal of Experimental Medicine ·Susan R. Webb,Katherine L. Molnar-Kimber,Jennifer Bruce,Jonathan Sprent,Darcy B. Wilson	55
20	Absence of H-2 restriction in primary and secondary mixed-lymphocyte reactions to strong M1s determinants. 1980 ·The Journal of Experimental Medicine ·Katherine L. Molnar-Kimber,Jonathan Sprent	51

About Katherine L. Molnar-Kimber

Katherine L. Molnar-Kimber is a scholar working on Genetics, Biotechnology and Infectious Diseases, having authored 37 papers that have together received 2.1k indexed citations. Recurring topics across this work include Virus-based gene therapy research (21 papers), Hepatitis B Virus Studies (7 papers) and Herpesvirus Infections and Treatments (6 papers). The work is most often cited by research in Genetics (1.1k citations), Biotechnology (284 citations) and Oncology (577 citations). Katherine L. Molnar-Kimber has collaborated with scholars based in United States, Canada and Israel. Frequent co-authors include Steven Μ. Albelda, William S. Mason, Larry R. Kaiser, Barry M. Weichman, Jesse Summers, Kunjlata M. Amin, Daniel H. Sterman, James M. Wilson, Jonathan Sprent and Eugene Kang. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and The Journal of Experimental Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact